证券代码：300584 证券简称：海辰药业 公告编号：2023-028 南京海辰药业股份有限公司 基于对公司未来发展的信心及对公司价值的充分认可,促进公司持续、稳定、 健康发展，以实际行动维护资本市场稳定和公司股东利益，公司控股股东、实际 控制人及持有公司股份的其他董监高自愿承诺:自签订承诺书起六个月内(即 2023 年 9 月 14 日至 2024 年 3 月 13 日)不减持本人直接持有的公司股份，包括 承诺期间该部分股份因资本公积转增、派送股票红利、配股、增发等事项产生的 新增股份。 二、上市公司董事会责任 公司董事会将督促上述人员严格遵守承诺，并按照《公司法》、《证券法》 以及中国证监会、深圳证券交易所相关法律法规、规范性文件的规定，及时履行 相关信息披露义务。 三、备查文件 1、上述承诺主体出具的《关于未来六个月内不减持公司股份的承诺函》。 特此公告！ 关于公司控股股东、实际控制人及董监高 承诺不减持公司股份的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 南京海辰药业股份有限公司（以下简称"公司"）近日收到了公司控股股东、 实际控制人曹于平先 ...

Financial Performance - The company's operating revenue for the first half of 2023 was ¥261,547,849.93, a decrease of 2.25% compared to ¥267,578,608.53 in the same period last year[24]. - Net profit attributable to shareholders increased by 9.89% to ¥19,474,926.52 from ¥17,721,523.59 year-on-year[24]. - Basic and diluted earnings per share rose by 9.88% to ¥0.1623 compared to ¥0.1477 in the same period last year[24]. - The net profit attributable to shareholders was 19.47 million yuan, an increase of 9.89% year-on-year, while the net profit excluding non-recurring items rose by 11.05% to 18.88 million yuan[40]. - The company reported a total comprehensive income of CNY 19,474,926.00 for the first half of 2023, compared to CNY 17,721,523.50 in the same period of 2022, representing an increase of approximately 9.9%[172]. - The company's total comprehensive income for the first half of 2023 was CNY 28,321,181.14, compared to CNY 23,847,193.40 in the same period of 2022, reflecting an increase of 18.3%[165]. Cash Flow and Investments - The net cash flow from operating activities improved significantly to ¥6,280,246.52, a turnaround of 118.13% from a negative cash flow of ¥34,649,138.87 in the previous year[24]. - The cash inflow from financing activities in the first half of 2023 was CNY 106,000,000.00, while cash outflow for debt repayment was CNY 79,000,000.00, resulting in a net inflow of CNY 19,956,587.86[170]. - The net cash flow from investment activities for the first half of 2023 was CNY 51,904,399.82, compared to CNY 119,114,493.60 in the same period of 2022, indicating a decrease of approximately 56.4%[170]. - Investment activities resulted in a net cash outflow of CNY -27,868,369.08, a decline from a net inflow of CNY 115,658,146.82 in the first half of 2022[167]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,321,048,611.92, reflecting a 2.09% increase from ¥1,293,945,410.29 at the end of the previous year[24]. - The total liabilities increased to CNY 350,889,636.48 from CNY 343,379,013.86, reflecting a rise of approximately 2.2%[154]. - The company's equity attributable to shareholders reached CNY 970,158,975.44, up from CNY 950,566,396.43, indicating an increase of about 2.1%[154]. - Current assets totaled CNY 394,041,482.02, up from CNY 378,378,861.18, indicating an increase of about 4.4%[152]. - The company's short-term borrowings rose to CNY 157,120,774.96 from CNY 120,095,819.46, marking an increase of about 30.8%[154]. Research and Development - The management highlights ongoing efforts in research and development to enhance product offerings and market competitiveness[17]. - Research and development expenses increased by 53.65% to ¥28,008,748.18, attributed to the initiation of multiple new R&D projects[61]. - The company is actively investing in R&D to enhance product quality and competitiveness, with one product approved during the reporting period[46]. - The company has developed a new synthesis process for Tigecycline, becoming one of the few domestic companies capable of stable production of both the raw material and formulation[46]. - The company plans to continue focusing on R&D and market expansion strategies to drive future growth[162]. Market and Product Development - The company has 66 approved formulations and 13 active pharmaceutical ingredients, focusing on therapeutic areas such as cardiovascular, diuretics, anti-infection, digestive system, immune regulation, diabetes, and orthopedics[32]. - The company’s main products include injectable Labetalol, Torasemide, Rivaroxaban, Tigecycline, and Cefoperazone Sodium, with a strong emphasis on clinical value and innovation[32]. - The sales of key products, including injection-grade Labetalol, Rivaroxaban tablets, and Tigecycline, showed significant growth compared to the same period last year, positively impacting the company's performance[41]. - The company is in the registration process for several drugs, including injection-grade Azithromycin and Torasemide, which are expected to enrich its product pipeline[47]. Environmental Compliance - The company emphasizes the importance of environmental compliance and plans to increase investment in environmental protection measures[81]. - The company has obtained relevant environmental protection administrative permits, including a pollution discharge permit valid until August 31, 2027[93]. - The company has established a wastewater treatment facility to manage and reduce pollutant discharge effectively[95]. - The company has implemented measures to ensure that all emissions are compliant with GB/T319-62-2015 standards[95]. - The company has conducted multiple emergency response drills for environmental incidents and revised its emergency measures accordingly[100]. Shareholder and Governance - The company emphasizes the protection of shareholder interests and has established a governance structure to ensure compliance with laws and regulations[103]. - The company held its annual general meeting on May 15, 2023, with an investor participation rate of 52.68%[86]. - The company plans not to distribute cash dividends or issue bonus shares for the first half of the year[88]. - The company has not engaged in any derivative investments or entrusted loans during the reporting period[74][75]. Risks and Challenges - The company faces risks including changes in industry policies, new drug development risks, and market share decline of its main product, Torasemide[5]. - The company acknowledges risks from management expansion and aims to improve its management model to adapt to growth[81]. - The company plans to enhance its R&D capabilities and expedite the registration process for Torasemide tablets to mitigate market share decline[79].

南京海辰药业股份有限公司 2023年1-6月非经营性资金占用及其他关联资金往来情况汇总表 非经营性资金占用 资金占用方名称 占用方与上市公司的 关联关系 上市公司核算的 会计科目 2023年期初往来 资金余额 2023年1-6月往来累 计发生金额（不含 利息） 2023年1-6月往 来资金的利息 （如有） 2023年1-6月偿 还累计发生金额 2023年6月末往 来资金余额 占用形成原因 占用性质 小计 小 计 0.00 其他关联方及其附属企业 小 计 总计 0.00 0.00 0.00 0.00 其它关联资金往来 资金往来方名称 往来方与上市公司的 关联关系 上市公司核算的 会计科目 2023年期初往来 资金余额 2023年1-6月往来累 计发生金额（不含 利息） 2023年1-6月往 来资金的利息 （如有） 2023年1-6月偿 还累计发生金额 2023年6月末往 来资金余额 往来形成原因 往来性质 镇江德瑞药物有限公司 子公司 其他应收款 6,151.99 11,672.86 10,740.98 7,083.87 往来款 非经营性往来 安徽海辰药业有限公司 子公司 其他应收款 3,500.00 3,63 ...

证券代码：300584 证券简称：海辰药业 公告编号：2023-027 南京海辰药业股份有限公司 关于 2023 年度对下属子公司提供担保额度预计的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、担保额度预计情况 1、南京海辰药业股份有限公司（以下简称"公司""海辰药业"）于 2023 年 8 月 22 日召开了第四届董事会第九次会议，审议通过了《关于 2023 年度对下 属子公司提供担保额度预计的议案》，为满足公司及子公司经营和业务发展需求， 保证生产经营活动顺利开展，预计 2023 年度为全资子公司安庆汇辰药业有限公 司（以下简称"安庆汇辰"）提供额度不超过 5,000 万元人民币（或等值外币） 的担保，以上担保额度事项的期限为一年，在最高限额内可循环滚动使用，担保 范围包括但不限于申请综合授信、贷款、承兑汇票、信用证等融资业务，实际担 保金额、种类、期限等以签署的协议为准，同时授权公司董事长或董事长指定的 授权代表人代表公司办理相关手续、签署相关法律文件。 2、根据《深圳证券交易所创业板股票上市规则》、《公司章程》等相关规 定，本次担保预计额度 ...

独立董事关于第四届董事会第九次会议 相关事项的独立意见 根据《上市公司独立董事规则》《上市公司治理准则》、深圳证券交易所《创 业板股票上市规则》、深圳证券交易所《上市公司自律监管指引第 2 号——创业 板上市公司规范运作》《关于规范上市公司对外担保行为的通知》（证监发 [2005]120 号）、以及《公司章程》《独立董事工作制度》等相关法律法规、规 章制度的有关规定，我们作为南京海辰药业股份有限公司（以下简称"公司"） 的独立董事，基于独立判断的立场，本着实事求是的原则，对公司下列事项进行 了认真核查和了解，并对公司相关事项发表了如下独立意见： 南京海辰药业股份有限公司 三、对《2023 年度对下属子公司提供担保额度预计的议案》的独立意见 公司本次担保额度预计是为满足下属子公司日常生产经营的资金需求，有利 于子公司业务开展，符合公司整体发展战略，不会对公司的正常运作造成不利影 响。本次被担保对象为公司合并报表范围内的子公司，资信状况良好，为其提 供 担保的财务风险处于公司可控范围内。本次担保额度预计事项的审议和表决程 序符合相关法律法规及《公司章程》的规定，不存在损害公司及股东特别是中小 股东利益的情形。我们 ...

证券代码：300584 证券简称：海辰药业 公告编号：2023-025 南京海辰药业股份有限公司 5、本次会议的召集、召开和表决程序符合《中华人民共和国公司法》等法 律法规和《公司章程》的有关规定。 二、董事会会议审议情况 会议审议并通过如下议案： 1、审议通过《2023 年半年度报告全文及摘要的议案》 第四届董事会第九次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1、本次董事会由董事长曹于平先生召集，会议通知于 2023 年 8 月 11 日电 话、电子邮件、专人送达等形式送达至各位董事，董事会会议通知中包括会议的 相关材料，同时列明了会议的召开时间、地点、内容和方式。 2、本次董事会于 2023 年 8 月 22 日在公司会议中心三楼会议室召开，本次 会议采取现场结合通讯表决方式召开。 3、本次董事会应出席 7 人，实际出席会议人数为 7 人，其中毛凌霄以通讯 表决方式参会。 4、本次董事会由董事长曹于平先生主持，公司高级管理人员、证券部工作 人员列席了会议。 经审核，董事会认为编制和审核南京海辰药业股份有限公司 ...

证券代码：300584 证券简称：海辰药业 公告编号：2023-026 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 1、本次监事会由监事会主席罗艳女士召集，会议通知于 2023 年 8 月 11 日 电话、电子邮件、专人送达等形式送达至各位董事，董事会会议通知中包括会议 的相关材料，同时列明了会议的召开时间、地点、内容和方式。 南京海辰药业股份有限公司 第四届监事会第九次会议决议公告 2、本次监事会于 2023 年 8 月 22 日在公司会议中心三楼会议室召开，本次 会议采取现场结合通讯表决方式召开。 3、本次监事会应出席 3 人，实际出席会议人数为 3 人，其中褚源红以通讯 表决方式参会。 4、本次监事会由监事会主席罗艳女士主持。 5、本次会议的召集、召开和表决程序符合《中华人民共和国公司法》等法 律法规和《公司章程》的有关规定。 二、监事会会议审议情况 会议审议并通过如下议案： 1、审议通过《2023 年半年度报告全文及摘要的议案》 监事会审核后认为：公司董事会对《2023 年半年度报告全文》的编制和审核 程序符合法律、行政法规 ...

证券代码：300584 证券简称：海辰药业 南京海辰药业股份有限公司 2022 年度网上业绩说明会 暨投资者关系活动记录表 编号：2023-001 | 投资者关系活 | □特定对象调研 □分析师会议 | | --- | --- | | 动类别 | □媒体采访 √业绩说明会 | | | □新闻发布会 □路演活动 | | | □现场参观 □其他 （请文字说明其他活动内容） | | 参与单位名称 及人员姓名 | 通过同花顺上市公司路演平台（https：//board.10jqka.com.cn/ir）参 | | | 加公司 2022 年度业绩说明会的投资者 | | 交流时间 | 年 月 日下午 至 2023 5 5 15：00 17：00 | | 地点 | 同花顺上市公司路演平台（https：//board.10jqka.com.cn/ir） | | | 公司董事长、总经理：曹于平先生 | | 上市公司参会 | 独立董事：赵鸣先生 | | 人员姓名 | 董事会秘书、副总经理：王立先生 | | | 财务总监：陈建仁先生 | | | 2022 年度网上业绩说明会互动交流主要问答如下： | | | 1、请问对公司股票的走 ...

Financial Performance - In 2022, the company achieved operating revenue of 526 million RMB, a year-on-year decrease of 8.97%[5] - The net profit attributable to shareholders was 32.45 million RMB, down 88.65% year-on-year, while the net profit excluding non-recurring gains and losses increased by 30.79% to 31.46 million RMB[5] - The significant decline in net profit was primarily due to a fair value change gain of 306.13 million RMB recognized in 2021, which contributed to a net profit of 260.21 million RMB that year[5] - The cash flow from operating activities was negative at -¥5,819,338.75, a decline of 109.71% from ¥59,940,771.89 in 2021[23] - The basic earnings per share dropped to ¥0.2704, down 88.65% from ¥2.3823 in 2021[23] - Total assets at the end of 2022 were ¥1,293,945,410.29, a slight decrease of 0.62% from ¥1,302,008,303.05 in 2021[23] - The company reported a total distributable profit of RMB 607,536,449.71 for the year, but did not propose any cash dividend distribution for 2022[154] Dividend and Shareholder Engagement - The company plans to distribute no cash dividends and no bonus shares for the year, with a capital reserve transfer of 0 shares for every 10 shares held[6] - The annual shareholders meeting had a participation rate of 62.17% on May 16, 2022[117] - The first extraordinary shareholders meeting had a participation rate of 62.04% on June 27, 2022[117] - The second extraordinary shareholders meeting also had a participation rate of 62.04% on July 15, 2022[118] - The company is committed to maintaining a high level of shareholder engagement as evidenced by the participation rates in meetings[117][118] Market and Product Development - The company aims to improve operational performance in 2023, despite the challenges faced in the previous year[5] - The company’s future outlook includes potential market expansion and new product development strategies[5] - The company is actively developing new products, with plans to submit consistency evaluation applications for several drugs in 2023, including Sodium Thiosulfate and Acetylcysteine injection[54] - The company has established a complete procurement, production, and sales system, ensuring stable supply and quality control in compliance with GMP standards[43][45] - The company is expanding its marketing network by developing partnerships with chain pharmacies and online channels, creating a multi-channel marketing strategy[49] Research and Development - The company has a strong R&D capability with over 60 dedicated personnel and has undertaken more than 20 national and provincial-level technology projects, enhancing its innovation in high-end generic and innovative drug development[46][47] - Research and development (R&D) investment amounted to ¥34,884,000.84 in 2022, representing 6.63% of operating revenue, a decrease from 10.01% in 2021[82] - The company has made significant progress in R&D projects, with multiple products nearing production approval, indicating a strong pipeline for future growth[80] - The company is focused on establishing quality standards for new raw materials and formulations, which is expected to enrich its product offerings[81] Regulatory Compliance and Risk Management - The management highlighted risks including changes in industry policies, new drug development risks, and a decline in market share for the main product Torasemide[5] - The company is committed to maintaining compliance with GMP standards and regulatory requirements from NMPA and FDA[17] - The company is aware of potential investment risks related to its new projects and will monitor market conditions closely[106] - The company emphasizes the importance of effective management and coordination as it expands its operations and increases the number of subsidiaries[106] Environmental Responsibility - The company has established comprehensive environmental management systems and complies with national and local environmental regulations[167] - The wastewater discharge meets the standards set by GB/T31962-2015 and DB32/939-2020, ensuring compliance with environmental laws[168] - The company has implemented measures to control emissions of volatile organic compounds (VOCs), with a total discharge of 3.42 tons, which is within the regulatory limits[169] - The company invested 1.7888 million yuan in environmental governance and protection during the reporting period[177] Governance and Management - The company has established a comprehensive governance structure, including a board of directors and supervisory board, to ensure effective decision-making and oversight[111] - The company has a performance evaluation and incentive mechanism for directors and senior management linked to company performance[113] - The company has implemented a profit distribution plan that considers both short-term and long-term shareholder interests[179] - The company has a structured governance framework, including a board of directors and an audit committee, to ensure compliance with laws and regulations[159] Employee Engagement and Welfare - Employee welfare initiatives included organizing multiple health check-ups and enhancing facilities such as a mother-baby room and fitness center[180] - The company organized 213 training sessions with a total of 1,084 training hours during the reporting period, aiming to enhance employee skills and company cohesion[149] - The total number of employees at the end of the reporting period is 549, with 437 in the parent company and 112 in major subsidiaries[147] - The company has a robust governance structure that includes a shareholders' meeting, board of directors, and supervisory board to protect minority shareholders' rights[179]

Financial Performance - The company's revenue for Q1 2023 was ¥117,201,090.18, a decrease of 22.18% compared to ¥150,605,102.60 in the same period last year[5] - Net profit attributable to shareholders was ¥12,213,813.89, down 3.23% from ¥12,620,961.53 year-on-year[5] - The company's basic and diluted earnings per share were both ¥0.1018, a decrease of 3.23% compared to ¥0.1052 in the same period last year[5] - Total operating revenue for Q1 2023 was ¥117,201,090.18, a decrease of 22.2% compared to ¥150,605,102.60 in Q1 2022[21] - Net profit for Q1 2023 was ¥12,213,813.89, slightly down from ¥12,448,499.59 in the same period last year, a decrease of 1.9%[22] Cash Flow - The net cash flow from operating activities improved significantly to ¥29,506,108.77, a 173.51% increase from a negative cash flow of -¥40,136,476.98 in the previous year[5] - Operating cash flow for Q1 2023 was ¥29,506,108.77, a significant improvement from a negative cash flow of ¥40,136,476.98 in Q1 2022[24] - The net cash flow from financing activities was ¥21,493,951.38, a 235.30% increase compared to -¥15,886,571.19 in the same period last year[9] - The net cash flow from investment activities was -53,605,687.16 CNY, compared to a net cash inflow of 23,247,822.60 CNY in the previous period[25] - Cash inflow from financing activities was 49,000,000.00 CNY, while cash outflow was 27,506,048.62 CNY, resulting in a net cash flow of 21,493,951.38 CNY[25] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,333,752,341.08, reflecting a 3.08% increase from ¥1,293,945,410.29 at the end of the previous year[5] - The total assets of the company as of March 31, 2023, were approximately 1.33 billion RMB, an increase from 1.29 billion RMB at the beginning of the year[18] - The company’s total liabilities increased to approximately 337.83 million RMB from 317.05 million RMB at the beginning of the year[18] - The total liabilities increased to ¥370,907,991.94 from ¥343,379,013.86, an increase of 8.1%[22] Equity - The total equity attributable to shareholders increased by 1.29% to ¥962,844,349.14 from ¥950,566,396.43 at the end of the previous year[5] - The total equity attributable to shareholders of the parent company rose to ¥962,844,349.14 from ¥950,566,396.43, an increase of 1.3%[22] Research and Development - Research and development expenses decreased by 37.09% to ¥3,013,143.82 from ¥4,789,264.33 year-on-year[9] - Research and development expenses were ¥3,013,143.82, down 37.5% from ¥4,789,264.33 in the previous year[21] Sales Performance - Sales of the product "Injectable Lantidilol 50mg" reached 340,600 units, with a sales amount of 47.78 million RMB, representing an 88% increase in volume and 89% increase in sales amount year-over-year[15] - Sales of "Rivaroxaban Tablets 15mg*7" decreased by 10% in both volume and sales amount, totaling 217,300 boxes and 13.36 million RMB[15] Shareholder Information - The largest shareholder, Mr. Cao Yuping, holds 42.08% of the shares, while the second-largest shareholder, Ms. Jiang Xiaoqin, holds 9.98%[11] Other Financial Metrics - The net profit excluding non-recurring gains and losses increased by 4.08% year-over-year to 12.57 million RMB[14] - Accounts receivable decreased from 185.38 million RMB at the beginning of the year to 167.74 million RMB[17] - The company’s cash and cash equivalents at the end of Q1 2023 were approximately 92.47 million RMB, down from 95.07 million RMB at the beginning of the year[17] - The total cash and cash equivalents at the end of the period amounted to 92,465,697.80 CNY, down from 113,795,568.27 CNY at the beginning of the period[25] - The company reported a decrease in cash and cash equivalents of -2,602,425.67 CNY for the quarter[25] Audit Information - The company did not conduct an audit for the first quarter report[26]